Azadbakht Leila, Atabak Shahnaz, Esmaillzadeh Ahmad
Department of Nutrition, School of Public Health, Isfahan University of Medical Sciences, Isfahan, P.O. Box 81745, Iran.
Diabetes Care. 2008 Apr;31(4):648-54. doi: 10.2337/dc07-2065. Epub 2008 Jan 9.
Several short-term trials on the effect of soy consumption on cardiovascular risks are available, but little evidence exists regarding the impact of long-term soy protein consumption among type 2 diabetic patients with nephropathy. To determine the effects of long-term soy consumption on cardiovascular risks, we measured C-reactive protein (CRP) and kidney function indexes among type 2 diabetic patients with nephropathy.
This longitudinal randomized clinical trial was conducted among 41 type 2 diabetic patients with nephropathy (18 men and 23 women). Twenty patients in the soy protein group consumed a diet containing 0.8 g protein/kg body weight (35% animal proteins, 35% textured soy protein, and 30% vegetable proteins) and 21 patients in the control group consumed a similar diet containing 70% animal proteins and 30% vegetable proteins for 4 years.
Soy protein consumption significantly affected cardiovascular risks such as fasting plasma glucose (mean change in the soy protein versus control groups: -18 +/- 3 vs. 11 +/- 2 mg/dl; P = 0.03), total cholesterol (-23 +/- 5 vs. 10 +/- 3 mg/dl; P = 0.01), LDL cholesterol (-20 +/- 5 vs. 6 +/- 2 mg/dl; P = 0.01), and serum triglyceride (-24 +/- 6 vs. -5 +/- 2 mg/dl; P = 0.01) concentrations. Serum CRP levels were significantly decreased by soy protein intake compared with those in the control group (1.31 +/- 0.6 vs. 0.33 +/- 0.1 mg/l; P = 0.02). Significant improvements were also seen in proteinuria (-0.15 +/- 0.03 vs. 0.02 +/- 0.01 g/day; P = 0.001) and urinary creatinine (-1.5 +/- 0.9 vs. 0.6 +/- 0.3 mg/dl, P = 0.01) by consumption of soy protein.
Longitudinal soy protein consumption significantly affected cardiovascular risk factors and kidney-related biomarkers among type 2 diabetic patients with nephropathy.
已有多项关于食用大豆对心血管风险影响的短期试验，但关于2型糖尿病肾病患者长期食用大豆蛋白的影响，证据较少。为了确定长期食用大豆对心血管风险的影响，我们测量了2型糖尿病肾病患者的C反应蛋白（CRP）和肾功能指标。
这项纵向随机临床试验在41例2型糖尿病肾病患者（18名男性和23名女性）中进行。大豆蛋白组的20名患者食用了一种饮食，其中每千克体重含0.8克蛋白质（35%为动物蛋白，35%为组织化大豆蛋白，30%为植物蛋白），对照组的21名患者食用了一种类似的饮食，其中70%为动物蛋白，30%为植物蛋白，为期4年。
食用大豆蛋白显著影响心血管风险，如空腹血糖（大豆蛋白组与对照组的平均变化：-18±3对11±2毫克/分升；P = 0.03）、总胆固醇（-23±5对10±3毫克/分升；P = 0.01）、低密度脂蛋白胆固醇（-20±5对6±2毫克/分升；P = 0.01）和血清甘油三酯（-24±6对-5±2毫克/分升；P = 0.01）浓度。与对照组相比，大豆蛋白摄入使血清CRP水平显著降低（1.31±0.6对0.33±0.1毫克/升；P = 0.02）。食用大豆蛋白还使蛋白尿（-0.15±0.03对0.02±0.01克/天；P = 0.001）和尿肌酐（-1.5±0.9对0.6±0.3毫克/分升，P = 0.01）有显著改善。
长期食用大豆蛋白显著影响2型糖尿病肾病患者的心血管危险因素和肾脏相关生物标志物。
